Next Phase Newsletter

A family office located in USA and is focused on helping female founders raise capital in the women’s health space. The firm typically makes investments ranging from $10-25K in the form of equity, convertible notes and SAFE notes. The firm planning to raise their first fund in 2022. The firm invests in both Pre-Seed and Seed rounds and invests in the US market.

The firm invests in seed stage, preferably in companies focused on women’s health. Within that arena, the firm is open to all 4 sectors and subsectors as they relate to women’s health and is agnostic to disease indication as well. The firm is not interested in pre-clinical or pre-prototype companies but is open to all three classes of medical devices on a case-by-case basis.

The firm is only interested in working with companies with female founders. With that being said, the firm is open to all types of management teams and is looking for companies that are working to improve patient outcomes. The firm is interested in co-investing and does not lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in California backs entrepreneurs applying deep and differentiated technology to transform giant industries. The firm focuses on seed and series A investments and has over $2B AUM. The firm usually makes seed investments in the range of $250K – $1M and venture-stage investments from $1M-$4M and may use both convertible notes or straight equity. The firm may lead or co-invest in a syndicate and looks to add unique value to entrepreneurs with a strong Equity Partner network, operational experience and technical background.

The firm invests in several verticals and is focused on deep technologies such as AI, advanced materials, quantum computing, etc. In the healthcare space, the firm is focused on the entire continuum including computational drug discovery, AI-driven diagnostics, better/faster clinical trials and technologies used by payers and providers to better understand and manage risk and drive better outcomes. The common theme is that the startup’s underlying technology be novel and data-driven. The firm does not invest in biopharma or traditional medical devices/diagnostics with a standard regulatory pathway.

The firm requires that startups have some type of proof-of-concept and traction, and prefers experienced/proven management teams and entrepreneurs that are introduced through the firm’s network. The firm typically seeks a board seat when leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A family office based in New York, NY is looking to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers companies that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A newly established venture capital firm founded in 2020 and is based in Barcelona, Spain. The firm is currently raising its first fund targeting €30M, and expects to close in mid to late 2021 and become fully operative. The firm is actively seeking investment opportunities and performing due diligence on companies they identify as a fit with the firm. The firm’s focus is in Seed to Series A financings and initial size of investment will be around €500K, and can invest up to €2.5M over the life of investment. The firm is open to USA-based opportunities but will focus on those based in Europe, Israel, and Spain where the firm is based.

The firm is exclusively interested in companies in the longevity space. In this regard, the firm is most interested in digital technologies including AI, robotics, data analytics, etc. Traditional therapeutics or devices do not fall within their investment priority, as the firm prefers to seek opportunities that leverage digital technologies to deliver novel therapeutic solutions (i.e. digital therapeutics). The firm is open to very early-stage, pre-revenue technologies and are open to university spin-offs/tech transfers.

The firm is backed by co-founders who have entrepreneurial backgrounds and can be a hands-on investor, assisting with company creation and other support as needed. When investing in companies that are not in geographical proximity to the firm, the firm prefers to co-invest alongside larger VC firms.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

The company was established as the pharmaceutical arm of a Japanese firm. The firm has a US licensing and clinical development office. The firm also has a Japan-based sales division. The pharma is seeking to form partnerships and in-licensing relationships regarding early stage assets in its key indication areas. These partnerships are highly flexible, and may involve the pharma contributing personnel, sharing studies and research tools, or providing research expense funding.

The pharma is interested in early-stage, first-in-class, orally active small molecule NCEs. The firm seeks assets in the following key areas: Metabolic / Cardiovascular Diseases (NASH, Heart failure (HFrEF, HFpEF, Hypertrophic cardiomyopathy), Diabetic Retinopathy / Diabetic Macular Edema, Chronic Kidney Disease, Sarcopenia), Autoimmune Diseases (Multiple Sclerosis, Lupus, IBD), CNS disorders (Alzheimer’s Disease, Schizophrenia). As well as drugs, the pharma is interested in drug targets in these disease areas. The firm is open to forming partnerships regarding very early stage assets, at or prior to the lead optimization phase. For in-licensing for the Japan market, the company is focused on renal diseases, dermatology and allergic diseases. The compay also invests in drug discovery technologies and research tools such as: technologies related to translational research using cell culture, isolated cellular organelles and related mechanisms; HTS technologies; protein structure analysis; chemical biology, chemical synthesis, and chemical libraries; biophysical tools; in silico technologies; biomarkers and bioinformatics screening, biomarker research, and compound libraries.

The company has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a Venture Capital company founded in 1996 and based in Menlo Park, California. The firm has raised 3 funds to date and is currently investing out of its 3rd that closed at $20M. The firm makes primarily equity investments ranging from $250,000 to $5 million over the lifetime of the investment, with $100K-$500K as an initial investment. The firm has closeting term relationships with several large Japanese medical technology corporations and also looks for ventures that they can introduce into the Japanese market. The firm prefers to invest in companies located in the West coast if the US, although they are also open to review opportunities in North America.

The firm is looking for seed and venture-stage medical and diagnostic device companies. In these areas, the firm is most interested in single use therapeutic devices. The preferred regulatory pathway is a 510(k) submission, but PMA applications are also considered. Sectors with the most interest would be interventional cardiovascular and neurovascular devices, less invasive surgical instrumentation, and point of care diagnostics. The firm remains open-minded to other types of devices and indications as well.

The firm looks for professionalism in a venture’s management team and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat in portfolio companies, however they look to add value by developing corporate partnerships in Japan at the appropriate time.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A new founded US fund of an Asia-based healthcare-focused venture capital firm. The firm seeks to make equity investments into early-stage life science companies. The sweet spot is seed to series B and the typical check size ranges from $5 – $10 million USD. The firm focuses on US, Canada or EU based companies. The firm prefers to co-invest or syndicate with other well-known investors.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics and Medical Technology. Digital Health and purely technology companies are less of interest.

The firm is open to work will entrepreneurs with all experience levels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.